| Kelsey Marie Denning, WHNP | |
|
1125 Atlantic Ave, Atlantic City, NJ 08401-4806 | |
| (609) 348-0066 | |
| (609) 348-1157 |
| Full Name | Kelsey Marie Denning |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 7 Years |
| Location | 1125 Atlantic Ave, Atlantic City, New Jersey |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619401833 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LW0102X | Nurse Practitioner - Women's Health | 26NR16753500 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lifeline Medical Associates Llc | 1456332170 | 157 |
News Archive
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.
A new study finds children who survive cancer have about twice the rate of educational and social problems compared to children without a history of cancer.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
› Verified 6 days ago
| Entity Name | Lifeline Medical Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821041617 PECOS PAC ID: 1456332170 Enrollment ID: O20040528000067 |
News Archive
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.
A new study finds children who survive cancer have about twice the rate of educational and social problems compared to children without a history of cancer.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
› Verified 6 days ago
| Entity Name | Southern Jersey Family Medical Centers, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568473973 PECOS PAC ID: 0547170763 Enrollment ID: O20040917000774 |
News Archive
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.
A new study finds children who survive cancer have about twice the rate of educational and social problems compared to children without a history of cancer.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelsey Marie Denning, WHNP 1 N White Horse Pike, Hammonton, NJ 08037-1875 Ph: (609) 567-0200 | Kelsey Marie Denning, WHNP 1125 Atlantic Ave, Atlantic City, NJ 08401-4806 Ph: (609) 348-0066 |
News Archive
Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the United States Patent and Trademark Office of Patent Application Serial No. 12/549458 entitled: " N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL)- METHOXYCARBONYL—AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."
Resverlogix Corp. announces that the Company's Phase 2 clinical trial, called ASSURE (ApoA-1 Synthesis Stimulation in Acute Coronary Syndrome patients), has made important modifications to the design of the trial which have the potential to demonstrate a more powerful endpoint for the planning of future clinical trials for RVX-208.
A new study finds children who survive cancer have about twice the rate of educational and social problems compared to children without a history of cancer.
Researchers at Moffitt Cancer Center have found that a deficiency in an important anti-tumor protein, p53, can slow or delay DNA repair after radiation treatment. They suggest that this is because p53 regulates the expression of two enzymes (JMJD2b and SUV39H1) that control the folding of DNA.
› Verified 6 days ago
Mr. Matthew R Soos, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-572-8600 | |
Helene E Fedele, ACNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 2922 Atlantic Ave, 2nd Floor, Atlantic City, NJ 08401 Phone: 609-437-2020 Fax: 609-345-4290 | |
Nediya Griffith, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 2009 Bacharach Blvd, Atlantic City, NJ 08401 Phone: 609-344-5714 Fax: 609-575-6033 | |
Marisa B Scibilia, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave., Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Debra Walters-olaru, APN Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 801 Boardwalk, Showboat Wellness Center, Atlantic City, NJ 08401 Phone: 609-343-4003 | |
Kelli L Gramlich, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8023 | |
Elaina M Nixon, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1925 Pacific Ave, Atlantic City, NJ 08401 Phone: 609-441-8146 |